Company intelligence / Profile preview

OncoHost

Ownership: Private
Development stage: Commercial

Overview

OncoHost has developed and commercialized the PROphet® precision oncology diagnostic platform. This blood-based test uses high-throughput proteomics (~7,000 proteins analyzed per sample) and machine learning to predict which patients with advanced cancers—starting with non-small cell lung cancer—are likely to benefit from PD‑1/PD‑L1 inhibitor therapies. The technology provides actionable insights before treatment initiation, aiming to overcome resistance mechanisms and improve patient outcomes. Clinical validation includes a large global trial network.

Therapeutic areas: Oncology
Modalities: Proteomics-based diagnostics
Industry: Protein Biomarker Diagnostics

Partnerships

None publicly disclosed beyond clinical trial network

Beyond the preview

Go deeper on OncoHost.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoHost.

Explore the full profile